Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

Inclusion Criteria: * Histological or cytological diagnosis of thoracic or abdominal tumor * At least medium amount of malignant pleural effusion or ascites * ECOG Performance Status 0-2 * Life expectancy ≥ 2 months * Adequate hematologic, cardiac, renal, and hepatic function * No major surgery within 4 weeks prior to this study * Written informed consent Exclusion Criteria: * Patients with central nervous system (CNS) metastases * Evidence of bleeding diathesis, serious infection * Evidence of myocardial infarction, unstable angina or cardiac insufficiency * Presence of serious COPD and/or respiratory failure * Allergic to study drug * Pregnant or lactating women * Participation in other clinical trials within 30 days prior to this study